Please Note:

The Open Access Repository will be moving to a new authentication system on the 1st of November.

From this date onwards, account holders will be required to login using their University of Tasmania credentials.
If your current repository username differs from your University username, please email E.Prints@utas.edu.au so we can update these details on your behalf.

Due to the change, there will be a short outage of the repository from 9am on the morning of the 1st of November

Open Access Repository

B-cell-targeted therapy for systemic lupus erythematosus: an update

Downloads

Downloads per month over past year

Ding, C and Foote, SJ and Jones, G (2008) B-cell-targeted therapy for systemic lupus erythematosus: an update. Osteoarthritis and Cartilage, 22 (4). pp. 239-249. ISSN 1173-8804

[img]
Preview
PDF
Ding_Biodrugs.pdf | Download (362kB)
Available under University of Tasmania Standard License.

Abstract

Systemic lupus erythematosus (SLE) is a classic autoimmune disease characterized by a myriad of immune system aberrations, most likely resulting from pathogenic autoantibody production, immune complex deposition, and subsequent end-organ damage. B cells play a key role in the pathogenesis; therefore, B-cell-targeted therapies, including B-cell depletion and blockage of B-cell survival factors such as B-lymphocyte stimulator (BLyS), are potential therapeutic targets for SLE. In uncontrolled clinical trials from approximately 20 studies, rituximab - a mouse-human chimeric anti-CD20 monoclonal antibody that effectively depletes B cells - has been demonstrated to reduce disease activity and decrease serum autoantibodies, with a clinical response of 86% in a case series of approximately 400 SLE patients with refractory disease, with or without concomitant use of cyclophosphamide. Epratuzumab, a humanized anti-CD22 monoclonal antibody that partially depletes B cells, has also been shown to reduce disease activity but not to decrease autoantibody levels in patients with moderately active SLE. Randomized controlled phase I/II trials in patients with active SLE have documented that belimumab, a humanized anti-BLyS monoclonal antibody, reduces B-cell numbers, inhibits disease activity and decreases anti-double-stranded DNA autoantibody in SLE patients. All these therapies are well tolerated, but accompanying infectious complications have been observed. Other B-cell-targeted therapies such as 'humanized' monoclonal antibodies to CD20 (e.g. ocrelizumab) and agents that interrupt B-cell/T-cell interactions also have potential, and the efficacy of these, along with rituximab, belimumab and epratuzumab, needs to be determined by randomized controlled trials.

Item Type: Article
Journal or Publication Title: Osteoarthritis and Cartilage
Page Range: pp. 239-249
ISSN: 1173-8804
Additional Information:

Copyright 2008 Adis Data Information BV.

Date Deposited: 28 Jan 2009 22:25
Last Modified: 18 Nov 2014 03:55
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP